SynthesisSurgical endoscopy2026
The incidence of gastric neoplastic lesions in autoimmune gastritis: a systematic review and meta-analysis.
Synthesis in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
BACKGROUND AND
objectiveAutoimmune gastritis (AIG) constitutes a distinct, immune-driven chronic gastritis marked by persistent and protracted mucosal inflammation, which can lead to gastric mucosal damage and potentially result in gastric neoplastic lesions. Pernicious anemia (PA) is considered the advanced stage of AIG. This study aims to summarize the incidence of gastric neoplastic lesions in AIG and PA patients.
methodsSearches were finalized on 15 April 2025 within the following repositories: PubMed, Embase, and Web of Science. The incidence of gastric neoplastic lesions served as the primary outcome; subgroup tests and meta-regression traced heterogeneity origins.
resultsA total of 18 studies were included. In AIG patients, the incidence rates of gastric cancer (GC), low-grade dysplasia (LGD), and gastric neuroendocrine tumors (NETs) were 289.60, 657.44, and 1154.93 per 100,000 person-years, respectively. In PA patients, the corresponding incidence rates were 156.25, 1350.46, and 437.00 per 100,000 person-years. In PA studies, prospective design and the application of endoscopic histological examination improved GC detection rates. Meta-regression analysis showed that the incidence of GC in the PA population and NETs in the AIG population increased with more recent study enrollment periods, suggesting that advances in endoscopic diagnostic technology may have facilitated lesion detection. Helicobacter pylori (HP) status did not significantly affect these risks.
conclusionThis study provides preliminary evidence of gastric neoplastic lesions in AIG patients. Rising GC incidence over time likely reflects improved endoscopic detection. These data inform clinical risk assessment and management strategies. Future research should standardize diagnostic criteria, account for comorbid autoimmune conditions, and reduce inter-study heterogeneity to better quantify risk in both AIG and PA populations.
Indexed as
Identifiers
42493616What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.